Articles: chronic.
-
Bronchiectasis PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Bronchiectasis are defined as permanent, abnormal dilation of bronchi and bronchioles. Laenec in 1819, the first described them as a very common disease before the age of antibiotics. Today is a minor problem in developed countries in opposition to developing countries. The purpose of this study is to determine the prevalence of bacteria in patients with non-CF bronquiectacias. ⋯ The following authors have nothing to disclose: Georgina Gramblicka, Daniela Visentini, Valeria Morandi, Maria Laura Grodnitzky, Gabriela Tabaj, Patricia Malamud, Ana Sangoy, Andrea Appendino, Laura Biglieri, Silvia GuaycocheaNo Product/Research Disclosure Information.
-
ILD Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: The cryptogenic organizing pneumonia (COP) is a disease characterized by impairment of alveolar ducts and terminal bronchioles with inflammation. It was previously known as bronchiolitis obliterans organizing pneumonia (BOOP). It affects men and women with the same incidence and may be secondary to infections, drugs or be a primary manifestation. This case report presents a patient with COP whose approach dispensed, in accordance with the patient, lung biopsy for diagnosis. Only clinical data,laboratorial and image exams were used to define the conduct. ⋯ The patient improved dramatically after introduction of corticosteroid therapy, which has been decreasing gradually in posology. This case expresses an opportunity for choice by the patient, along with the physician and scientific evidence, to a personal approach for this disease.Reference #1: Vasu TS, Cavallazzi R, Hirani A, Sharma D, Weibel SB, Kane GC. Clinical and radiologic distinctions between secondary bronchiolitis obliterans organizing pneumonia and cryptogenic organizing pneumonia. Respir Care. 2009.Reference #2: Oymak FS, Demirbas HM, Mavili E, et al. Bronchiolitis obliterans organizing pneumonia. Clinical and roentgenological features in 26 cases. Respiration. 2005;723:254-262Reference #3: Sveinsson OA, Isaksson HJ, Sigvaldason A, Yngvason F, Aspelund T, Gudmundsson G. Clinical features in secondary and cryptogenic organising pneumonia. Int J Tuberc Lung Dis. 2009DISCLOSURE: The following authors have nothing to disclose: Gilmar Zonzin, Christian Boechat, Gabriela de Souza, Silvio Guerra, Priscila das Virgens, Jamile Abdalla, Vinícius AgostinhoNo Product/Research Disclosure Information.
-
Pleural Disease/Pneumothorax PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Pneumothorax continues to be a major cause of morbidity and mortality among the respiratory patients but there is paucity of data regarding aetiology, clinical profile, management and outcome of Spontaneous Pneumothorax (SP) from this part of the world. Therefore, this study was carried out to determine the aetiology, clinical presentation, management and outcomes of Spontaneous pneumothorax in a tertiary care Hospital from eastern India. ⋯ The following authors have nothing to disclose: Aparup Dhua, Sourin Bhuniya, Arunabha Datta Chaudhuri, Sumit Raytapadar, Tapan Das BairagyaNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Sustained bronchodilation is thought to contribute to the reduction in exacerbations in patients with chronic obstructive pulmonary disease (COPD). Here we evaluate the effect of once-daily QVA149, a dual bronchodilator fixed-dose combination of indacaterol and glycopyrronium, on lung function and exacerbation rates in comparison with tiotropium. ⋯ Jadwiga Wedzicha: Consultant fee, speaker bureau, advisory committee, etc.: JW has received speaking fee and/or for advisory boards from GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Boehringer Ingelheim, Nycomed. Chiesi and Respifor as well as travel reimbursements from Boehringer Ingelheim. JW has received research grants from GlaxoSmithKline, AstraZeneca, Chiesi and Novartis. Angel FowlerTaylor: Employee: Novartis employee Peter D'Andrea: Employee: Novartis employee Christie Arrasate: Employee: Novartis employee Hungta Chen: Employee: Novartis employee Donald Banerji: Employee: Novartis employee The following authors have nothing to disclose: Joachim FickerNo Product/Research Disclosure Information.
-
Cardiovascular Disease PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The risk of stroke associated to the various means of cardiac stimulation is still limited and offers only tendencies. It is only known that patients with sinus node dysfunction are in risk of stroke and suggest that ventricular demand pacemakers do not offer protection against this risk. ⋯ The following authors have nothing to disclose: Elieusa Sampaio, Roque Aras Júnior, José Alberto da Matta, Cristiano Macedo, Márcia Maria Oliveira, Ubiratan dos Santos Júnior, Sérgio CâmaraNo Product/Research Disclosure Information.